Product Overview
This research-grade peptide combination is supplied exclusively for laboratory and experimental use. The CJC-1295 and Ipamorelin combination is studied in experimental models focused on coordinated growth hormone release and anabolic signaling dynamics. Research interest includes how multiple secretagogue pathways influence long-term endocrine communication.
CJC-1295 + Ipamorelin is a dual-peptide blend commonly utilized in controlled experimental settings to investigate coordinated interactions within growth hormone–related signaling pathways. CJC-1295 is a synthetic tetrasubstituted peptide analog of GHRH, designed to support prolonged receptor engagement through increased stability. Ipamorelin is a selective GHSR (growth hormone secretagogue receptor) agonist frequently explored for its high receptor specificity and minimal off-target binding profile in laboratory assays.
Combined in a 10 mg (CJC-1295) + 5 mg (Ipamorelin) format, the blend enables researchers to examine multi-pathway activation dynamics involving both GHRH-mediated and ghrelin-mimetic mechanisms, offering a complementary model for studying pulsatile GH release patterns, receptor synergy, and peptide pharmacokinetics under controlled experimental conditions.
Scientific Description
CJC-1295 is a modified peptide incorporating Drug Affinity Complex (DAC) technology in some research variants, enhancing its plasma stability and receptor interaction time frame. It engages GHRH receptors (GHRH-R), influencing intracellular signaling cascades such as cAMP–PKA, CREB activation, and downstream transcriptional pathways related to somatotropic axis modulation.
Ipamorelin, a pentapeptide secretagogue, selectively binds GHSR-1a and exhibits high specificity for this receptor compared to earlier GHRP-class compounds. In vitro studies frequently evaluate its selective suppression of off-target hormones while maintaining preserved ghrelin-receptor binding kinetics. The combined blend allows investigation of synchronized receptor activation events, GH pulse frequency modulation, and comparative potency across peptide classes.
Research Background
Experimental literature involving CJC-1295 and Ipamorelin commonly focuses on:
Receptor pathway synergy: GHRH-R and GHSR-1a co-activation and downstream signaling interplay.
Pharmacokinetic modeling: comparative half-life, stability, and degradation kinetics of individual and combined peptides.
Peptide–receptor binding profiles: selectivity, receptor affinity, and influence on intracellular messengers.
Pulsatile secretion patterning: simulation and mapping of growth-hormone–related pulsatility in vitro.
Structure–activity relationships (SAR): how substitutions and sequence motifs influence stability and function.
The blend format (10 mg + 5 mg) provides a practical ratio for comparative and combination-model research, enabling consistent experimental conditions across replicates.
Specifications & Identifiers
CJC-1295 - 10 mg
Molecular Formula: C152H252N44O42 Molar Mass: ~ 3367.9 g/mol CAS Number: 863288-34-0 PubChem ID: 56841945 Total Active Ingredient: 10 mg lyophilised peptide per vial
Ipamorelin 5 mg
Synonyms: Ipamorelin, NNC-26-0161, Growth Hormone Secretagogue Pentapeptide Molecular Formula: C38H49N9O5 Molar Mass: ~711.87 g/mol CAS Number: 170851-70-4 PubChem CID: 9831659 Total Active Ingredient: 5 mg lyophilised peptide per vial